-
Front Oncol: Real-world assessment of the long-term efficacy of first-line pembrolizumab monotherapy in advanced NSCLC patients with PD-L1 ≥ 50%
Time of Update: 2022-04-23
The study included two cohorts of patients: the electronic medical record cohort (EHR cohort) and the manual review cohort (spotlight cohort), and assessed overall survival (OS) in the two cohorts, and real-world progression-free survival (rwPFS) in the spotlight cohort and real-world Tumor Response (rwTR) .
-
FDA expands indications for Lynparza (olaparib)
Time of Update: 2022-04-23
's Lynparza (olaparib) to allow treatment of BRCA-mutated, HER2-negative, high-risk breast cancer patients who have already received chemotherapy.
Lynparza is already approved in the US, EU, Japan and several other countries for patients with gBRCAm, HER2-negative, metastatic breast cancer who have previously received chemotherapy .
-
J Clin Oncol: Pembrolizumab ± chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma
Time of Update: 2022-04-23
The phase 3 KEYNOTE-048 trial evaluated the overall efficacy of pembrolizumab in patients with recurrent or metastatic (R/M) head and neck sickle cell carcinoma (HNSCC) and according to PD-L1 combined positive score (CPS) Efficacy by group (CPS ≥ 1 point and CPS ≥ 20 points) .
-
FDA rejects sintilimab for NSCLC
Time of Update: 2022-04-23
FDA NSCLCThe companies are seeking approval of sintilimab in combination with chemotherapy for first-line treatment of adults with stage IIIB, IIIC or IV non-squamous non-small cell lung cancer .
-
Otol Neurotol: What are the patient-reported outcomes after cholesteatoma surgery?
Time of Update: 2022-04-23
Here, researchers from the University of Amsterdam and other units in the Netherlands explored the course of patient complaints, the impact of their complaints and audiometry, and the stability of audiometry, as well as changes over time in primary and recurrent/residual cholesteatoma after surgery .
-
J Clin Oncol: Replacing CT with MRI and lengthening the follow-up interval have no adverse effect on long-term outcomes in patients with stage I seminoma
Time of Update: 2022-04-23
The TRISST trial was a noninferiority, phase 3 factorial trial designed to assess whether the use of magnetic resonance imaging (MRI) or reduced frequency of scans did not increase the rate of late recurrence .
-
Clin Oncol: Efficacy of Nintedanib + Docetaxel Third-Line Therapy After Progression on Second-Line Immunotherapy for Advanced Lung Adenocarcinoma
Time of Update: 2022-04-23
Results from cohort B of the VARGADO study were recently published in Clinical Oncology, focusing on Nintedanib + docetaxel after progression on first-line chemotherapy and second-line immunotherapy in patients with locally advanced, metastatic, or locally recurrent lung adenocarcinoma efficacy of third-line therapy .
-
Nature sub-journal: South China University of Technology Wang Jun/Xiong Menghua and others develop pH-sensitive nano-detergents for cancer treatment
Time of Update: 2022-04-23
Materials with the activity of lysing cell membranes can induce the " kiss of death " to tumor cells and overcome the problems of tumor cell heterogeneity and drug resistance . However, these materia
-
If there are incidental pathological findings in young gynecomastia, should the pathological examination be a routine examination?
Time of Update: 2022-04-23
Table 1 Detailed findings of atypical hyperplastic lesions or ductal carcinoma in situ in young menFindings that may increase breast cancer risk were found in three male adolescents (1.
-
JAMA Netw Open: Correlation between plasma EBV DNA levels and prognosis in patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-PD-1 therapy
Time of Update: 2022-04-23
Studies have shown that plasma EBV DNA is a prognostic marker in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) receiving anti-PD-1 monotherapy and can be used to monitor disease progression .
-
Phase III study of tiragolumab combined with atezolizumab in extensive-stage small cell lung cancer failed (SKYSCRAPER-02 study)
Time of Update: 2022-04-23
The SKYSCRAPER-02 study will explore the efficacy of a new combination therapy regimen, Tiragolumab + Atezolizumab + chemotherapy, in extensive-stage small cell lung cancer .
The SKYSCRAPER-02 study will explore the efficacy of a new combination therapy regimen, Tiragolumab + Atezolizumab + chemotherapy, in extensive-stage small cell lung cancer .
-
Cancers: Line-field confocal optical coherence tomography improves accuracy and confidence in the diagnosis of basal cell carcinoma in suspicious lesions
Time of Update: 2022-04-23
The sensitivity and specificity of add-on LC-OCT to dermoscopy alone were compared to identify basal cell carcinoma in clinically unclear lesions .
Compared with dermoscopy alone, LC-OCT has significantly improved diagnostic confidence, sensitivity, and specificity in detecting basal cell carcinoma in clinically suspicious lesions .
-
PLOS Medicine: Large-scale study reveals artificial sweeteners linked to increased cancer risk
Time of Update: 2022-04-23
PLOS Medicine Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort studyThe use of artificial sweeteners can reduce the amount of added sugar and corresponding calories, but also maintain the sweetness, but this new study shows that some artificial sweeteners are associated with an increased risk of cancer .
-
"Dual-target combination" new indication approved in my country, "dabrafenib" combined with "trametinib" brings a new option for patients with BRAF V600 mutant non-small cell lung cancer
Time of Update: 2022-04-23
This is not only the third approved indication of Tefero® and Megenin® , but also the first dual-targeted combination therapy drug approved in China for BRAF V600 mutation-positive metastatic non-small cell lung cancer .
-
Inventory of PD-1/PD-L1 drugs - K, O, T, B, I, L, J drugs
Time of Update: 2022-04-23
(Figure II)The PD-1/PD-L1 axis can be modulated by various signals in cancer cells and plays a key role in tumorigenesis .
(Figure 3) PD-1/PD-L1 targeted inhibitors have been reported to play a key role in cancer .
-
NEJM: Effect of dalolutamide on survival in metastatic hormone-sensitive prostate cancer
Time of Update: 2022-04-23
CONCLUSIONS : In this trial involving patients with metastatic hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of dalolutamide, androgen deprivation therapy, and docetaxel than with placebo plus androgen deprivation therapy and more Setaxel, and the addition of dalolutamide resulted in an improvement in key secondary endpoints .
-
Nature sub-journal: Fitting bacteria with voice-activated switches for cancer treatment
Time of Update: 2022-04-23
DigestionRecently, Mikhail Shapiro 's team at the California Institute of Technology published a research paper entitled: Ultrasound-controllable engineered bacteria for cancer immunotherapy in the journal Nature Communications .
Mikhail Shapiro Nature Communications The research developed genetically engineered Escherichia coli to express tumor-inhibiting nanobodies and temperature-sensitive gene regulatory switches .
-
ESMO: Pembrolizumab Reduces Risk of Relapse or Death by 24% in Completely Resected, Early-Stage NSCLC (KEYNOTE-091)
Time of Update: 2022-04-23
CONCLUSIONS: Adjuvant pembrolizumab for completely resected stage IB (T ≥ 4 cm)-IIIA NSCLC patients regardless of PD-L1 expression (regardless of PD-L1 TPS <1%, 1-49%, ≥50% ) provided a statistically significant, clinically meaningful improvement in DFS .
-
Clin Cancer Res: Efficacy and safety of ramucirumab in the treatment of advanced biliary tract cancer
Time of Update: 2022-04-23
Biliary tract cancer (BTC) is a heterogeneous group of malignancies including intrahepatic cholangiocarcinoma (CCA), extrahepatic cholangiocarcinoma, and gallbladder carcinoma .
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy.
-
Good news for breast cancer patients!
Time of Update: 2022-04-23
Trastuzumab, Emmett, constantly explores the cure and survival of breast cancer patients. Using medical evidence to provide a strong backing for clinical diagnosis and treatment of early breast cance